Cargando…
The Efficacy of Rabbit Anti-Thymocyte Globulin for Acute Kidney Transplant Rejection in Patients Using Calcineurin Inhibitor and Mycophenolate Mofetil-Based Immunosuppressive Therapy
BACKGROUND: T cell depleting antibody therapy with rabbit anti-thymocyte globulin (rATG) is the treatment of choice for glucocorticoid-resistant acute kidney allograft rejection (AR) and is used as first-line therapy in severe AR. Almost all studies investigating the effectiveness of rATG for this i...
Autores principales: | van der Zwan, Marieke, Clahsen-Van Groningen, Marian C., Roodnat, Joke I., Bouvy, Anne P., Slachmuylders, Casper L., Weimar, Willem, Baan, Carla C., Hesselink, Dennis A., Kho, Marcia M.L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6248318/ https://www.ncbi.nlm.nih.gov/pubmed/30115901 http://dx.doi.org/10.12659/AOT.909646 |
Ejemplares similares
-
Comparison of Alemtuzumab and Anti-thymocyte Globulin Treatment for Acute Kidney Allograft Rejection
por: van der Zwan, Marieke, et al.
Publicado: (2020) -
Oxalate deposition in renal allograft biopsies within 3 months after transplantation is associated with allograft dysfunction
por: Snijders, Malou L. H., et al.
Publicado: (2019) -
Mycophenolate mofetil: safety and efficacy in the prophylaxis of acute kidney transplantation rejection
por: Dalal, Pranav, et al.
Publicado: (2009) -
Immune globulin/mycophenolate mofetil/rituximab: Breakthrough COVID-19: 2 case reports
Publicado: (2022) -
Clinical and Molecular Profiling to Develop a Potential Prediction Model for the Response to Alemtuzumab Therapy for Acute Kidney Transplant Rejection
por: Hullegie‐Peelen, Daphne M., et al.
Publicado: (2022)